Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Roivant Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Stay updated with breaking news from Multiple Ascending Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good day, and thank you for standing by. Welcome to the Roivant Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative retinal disease pipelineCompletes enrollment of Multiple Ascending Dose phase...
Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S a biotechnology company focused...
Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma...
Regulus Therapeutics Inc (NASDAQ: RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic